Restructuring events
European Restructuring Monitor (ERM)
The restructuring events database contains factsheets with data on large-scale restructuring events reported in the principal national media and company websites in each EU Member State. This database was created in 2002.
BioNTech, a German biotechnology company, has announced the elimination of 950 to 1,350 full-time positions worldwide BioNTech 2025 - WO by the end of 2027. In Germany, the sites in Marburg (250 to 350 out of a total of 670 jobs) and Idar-Oberstein (around 150 out of 450 jobs) are particularly affected. At the same time, approximately 350 new jobs are expected to be created at the company’s headquarters in Mainz.
The restructuring is driven by a decline in revenue due to falling demand for the Covid-19 vaccine and a significant increase in investment in the development of mRNA-based cancer therapies.
The workforce reduction will mainly occur through redundancies, although job relocations are also planned. No response from social partners has been reported so far.
As of the end of 2024, BioNTech employed approximately 7,200 people worldwide and is currently placing a strong focus on oncological research. The first marketing authorisations for cancer treatments are expected in 2026.
Eurofound (2025), BioNTech, Internal restructuring in Germany, factsheet number 202683, European Restructuring Monitor. Dublin, https://apps.eurofound.europa.eu/restructuring-events/detail/202683.